Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 8,974 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urogenital Neoplasms Clear all
Completed Phase 1 Interventional

Study to Assess PK, Safety and Tolerability in Patients With DM and CKD

NCT03795389
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe), Diabetes
Interventions
DM199
Drug
Lead sponsor
DiaMedica Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Hialeah, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 14, 2026, 1:43 PM EDT
Terminated Phase 1 Interventional

A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer

NCT01647789
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
CFG920
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
San Francisco, California • San Antonio, Texas • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 14, 2026, 1:43 PM EDT
Completed No phase listed Observational

Quality of Life and Symptom Management in Patients With Bladder Cancer

NCT00772018
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
David Latini
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 14, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional Results available

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

NCT04383210
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions
Seribantumab
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 14, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional Results available

Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer

NCT02766478
View directory record Official record
Conditions
Prostate Cancer
Interventions
Genistein, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 14, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

NCT00043368
View directory record Official record
Conditions
Melanoma, Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, T-Cell, Carcinoma, Non-Small-Cell Lung
Interventions
PF-3512676
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
31
States / cities
Berkely, California • Gilroy, California • Hollister, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 14, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin

NCT00971620
View directory record Official record
Conditions
Cutaneous Leiomyomas, Hereditary Leiomyomatosis and Renal Cell Cancer
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 14, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

NCT00039585
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
imatinib mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 14, 2026, 1:43 PM EDT
Completed No phase listed Observational

Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis

NCT02457715
View directory record Official record
Conditions
Prostate Cancer, Renal Cancer, Brain Cancer, ALS
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 14, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer

NCT03565835
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 14, 2026, 1:43 PM EDT
Not yet recruiting Not applicable Interventional

PRISM-NLM: Prostatectomy Intraoperative Surgical Margin Assessment With Non-linear Microscopy

NCT07516808
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nonlinear Microscope (NLM)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 14, 2026, 1:43 PM EDT
Recruiting Phase 2 Interventional

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

NCT05526989
View directory record Official record
Conditions
Penile Carcinoma
Interventions
Dostarlimab, Niraparib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 14, 2026, 1:43 PM EDT
Withdrawn Not applicable Interventional

Health Interventions in Men Undergoing Radical Prostatectomy

NCT01748110
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Urinary Incontinence
Interventions
Intensive Fitness Intervention, TRIMM
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 14, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

NCT03173560
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
lenvatinib, everolimus
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
Duarte, California • Whittier, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 14, 2026, 1:43 PM EDT
Not yet recruiting Phase 2 Interventional

Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy

NCT07639086
View directory record Official record
Conditions
Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)
Interventions
Sacituzumab Tirumotecan
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 14, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

NCT00569673
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, pegfilgrastim, docetaxel, trabectedin
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
37
States / cities
Burbank, California • Los Angeles, California • New Britain, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 14, 2026, 1:43 PM EDT
Active, not recruiting Phase 1 Interventional

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

NCT06421935
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
M9466, Tuvusertib, Abiraterone acetate, Prednisone/Prednisolone
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

NCT03935282
View directory record Official record
Conditions
Breast Neoplasm, Prostatic Neoplasm, Colorectal Neoplasms, Endometrial Neoplasms, Hodgkin Disease, Non Hodgkin Lymphoma
Interventions
AH-HA Tool in the EPIC EHR
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Fort Smith, Arkansas • Cedar Rapids, Iowa • Ballwin, Missouri + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 14, 2026, 1:43 PM EDT
Completed Early Phase 1 Interventional

Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer

NCT04282824
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Monosodium Glutamate, Positron Emission Tomography
Procedure · Drug · Dietary Supplement
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 14, 2026, 1:43 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

NCT02391480
View directory record Official record
Conditions
Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML), Multiple Myeloma, Prostate Cancer, Small Cell Lung Cancer, Non-Hodgkins Lymphoma
Interventions
ABBV-075, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Scottsdale, Arizona • Duarte, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 14, 2026, 1:43 PM EDT
Active, not recruiting No phase listed Observational

Cancer Driving Mutations in Endometriosis Lesions and Development of Progesterone Resistance

NCT03756480
View directory record Official record
Conditions
Endometriosis, Endometrial Diseases
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
135 participants
Timeline
2020 – 2027
U.S. locations
3
States / cities
New Haven, Connecticut • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 14, 2026, 1:43 PM EDT
Not listed Early Phase 1 Interventional

Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

NCT01422746
View directory record Official record
Conditions
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Metformin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 14, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

NCT04972097
View directory record Official record
Conditions
Prostate Cancer
Interventions
Irreversible Electroporation
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Orange, California • Aurora, Colorado • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 14, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

NCT03617913
View directory record Official record
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8, Stage II Urethral Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Urethral Urothelial Carcinoma
Interventions
Avelumab, Cisplatin, Fluorouracil, Mitomycin, Quality-of-Life Assessment, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 14, 2026, 1:43 PM EDT